IBI305

Innovent Biologics is a leading biopharmaceutical company based in China, dedicated to developing, manufacturing, and commercializing high-quality innovative medicines for oncology, metabolic, autoimmune, and other major diseases. Founded in 2011, the company has built a fully integrated platform and a robust pipeline of over 30 drug candidates, including several approved products such as Tyvyt (sintilimab) and Byvasda (IBI305). Innovent is recognized for its strategic global partnerships, most notably with Eli Lilly and Roche, to advance its therapeutic programs and expand its international footprint. The company operates large-scale, state-of-the-art manufacturing facilities that comply with international GMP standards, ensuring the production of affordable and high-quality biologics. With a strong focus on innovation, Innovent continues to expand its portfolio into diverse modalities, including bispecific antibodies and multi-target peptides.